Phage Therapy

Clinical Evidence#

Chronic prostatitis: Phage endolysins tested against biofilm-forming bacteria in chronic pelvic pain syndrome.^{[1]Stevens 2023 — Successful Use of a Phage Endolysin for Treatment of CPPS/Chronic Bacterial ProstatitisRoy H. Stevens, Hongming Zhang, Michal Kajsik et al. · 2023Open reference 1 ↓}

E. coli prostatitis case report: Phage therapy cleared dominant E. coli biofilm, unmasking co-infecting Serratia marcescens—demonstrating polymicrobial complexity.^{[2]Johri 2023 — Successful Treatment of Recurrent E. coli Infection with Bacteriophage Therapy for Chronic Bacterial ProstatitisApurva Virmani Johri, Pranav Johri, Naomi Hoyle et al. · 2023Open reference 2 ↓}

Safety/efficacy systematic review: Phage therapy is generally safe with favorable outcomes in compassionate-use settings, though RCT evidence remains limited.^{[3]Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic reviewSaartje Uyttebroek, Baisong Chen, Jolien Onsea et al. · 2022Open reference 3 ↓}

CRC virome: Altered bacteriophage communities in CRC, with phage-bacteria dynamics influencing tumor progression.^{[4]Alterations in colorectal cancer virome and its persistence after surgerySi Xian Ho, Jia-Hao Law, Chin-Wen Png et al. · 2024Open reference 4 ↓} Phage nanovectors: Engineered phage (M13) as drug delivery vehicles for photodynamic CRC therapy.^{[5]Molecular engineering of a spheroid-penetrating phage nanovector for photodynamic treatment of colon cancer cellsEleonora Turrini, Luca Ulfo, Paolo Emidio Costantini et al. · 2024Open reference 5 ↓}